Journal List > Tuberc Respir Dis > v.60(4) > 1000940

TOOLS
Kim, Yoon, Hur, Jung, Lee, Lee, Shin, Shim, In, Yoo, and Kang: The Role of Poly(ADP-ribose) Polymerase-1 in Ventilator-Induced Lung Injury
Original Article
Tuberculosis and Respiratory Diseases

Tuberculosis and Respiratory Diseases 2006; 60(4): 451-463.

Published online: 30 April 2006

DOI: https://doi.org/10.4046/trd.2006.60.4.451

The Role of Poly(ADP-ribose) Polymerase-1 in Ventilator-Induced Lung Injury

Je-Hyeong Kim, M.D., Dae Wui Yoon1, Gyu Young Hur, M.D., Ki Hwan Jung, M.D., Sung Yong Lee, M.D., Sang Yeub Lee, M.D., Chol Shin, M.D., Jae Jeong Shim, M.D., Kwang Ho In, M.D., Se Hwa Yoo, M.D., Kyung Ho Kang, M.D.

Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea.

1Institute of Human Genomic Study, Ansan Hospital, Korea University Medical Center, Ansan, Korea.

Address for correspondence: Kyung Ho Kang, M.D., Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University. #97, Gurodong-Gil, Guro-Gu, Seoul, Korea. Zip-code 152-703. Phone: 02-818-6638, Fax: 02-865-9670, kkhchest@korea.ac.kr

Received 23 January 2006       Accepted 24 April 2006

Copyright © 2006 The Korean Academy of Tuberculosis and Respiratory Diseases

Abstract

Background

Reactive oxygen species (ROS) take center stage as executers in ventilator-induced lung injury (VILI). The protein with DNA-damage scanning activity, poly (ADP-ribose) polymerase-1 (PARP1), signals DNA rupture and participates in base-excision repair. Paradoxically,overactivation of PARP1 in response to massive genotoxic injury such as ROS can induce cell death through β-nicotinamide adenine dinucleotide (NAD+) depletion, resulting in inflammation. The purpose of this study is to investigate the role of PARP1 and the effect of its inhibitor in VILI.

Methods

Forty-eight male C57BL/6 mice were divided into sham, lung protective ventilation(LPV), VILI, and PARP1 inhibitor (PJ34)+VILI (PJ34+VILI) groups. Mechanical ventilator setting for the LPV group was PIP 15 cmH2O + PEEP 3 cmH2O + RR 90/min + 2 hours. The VILI and PJ34+VILI groups were ventilated on a setting of PIP 40 cmH2O + PEEP 0 cmH2O + RR 90/min + 2 hours. As a PARP1 inhibitor for the PJ34+VILI group, 20 mg/Kg of PJ34 was treated intraperitoneally 2 hours before mechanical ventilation. Wet-to-dry weight ratio and acute lung injury (ALI) score were measured to determine the degree of VILI. PARP1 activity was evaluated by using an immunohistochemical method utilizing biotinylated NAD. Myeloperoxidase (MPO) activity and the concentration of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 were measured in bronchoalveolar lavage fluid (BALF).

Results

In the PJ34+VILI group, PJ34 pretreatment significantly reduced the degree of lung injury, compared with the VILI group (p<0.05). The number of cells expressing PARP1 activity was significantly increased in the VILI group, but significantly decreased in the PJ34+VILI group (p=0.001). In BALF, MPO activity, TNF-α, IL-1β, and IL-6 were also significantly lower in the PJ34+VILI group (all, p<0.05).

Conclusion

PARP1 overactivation plays a major role in the mechanism of VILI. PARP1 inhibitor prevents VILI, and decreases MPO activity and inflammatory cytokines.

Keywords: Ventilator-induced lung injury, Acute lung injury, Poly (ADP-ribose) polymerase-1, Poly (ADP-ribose) polymerase-1 inhibitor

Figures and Tables

Figure 1
In the setting of 40 cmH2O of peak inspiratory pressure, 0 cmH2O of positive end-expiratory pressure, and 90 per minute of respiration rate, the degree of ventilator-induced lung injury increased with the lapse of time. The findings of severe acute lung injury such as alveolar congestion, hemorrhage, infiltration of inflammatory cells and thickening of alveolar wall were most prominent at about 120 minutes after mechanical ventilation (hematoxylin and eosin stain, ×100).
trd-60-451-g001
Figure 2
Histopathologic examination shows high levels of intra-alveolar exudates, inflammatory infiltration, hemorrhage, and interstitial edema in the VILI group. In the LPV group, significant acute lung injury was absent and only mild inflammatory cellular infiltration was observed. The PJ34+VILI group shows a moderately higher level of inflammatory cell infiltration and congestion than the LPV group, while the overall degree of lung injury was significantly lower than the VILI group (hematoxylin eosin stain).
Sham: sham group, LPV: lung protective ventilation group, VILI: ventilator-induced lung injury group, PJ34+VILI: poly(ADP-ribose) polymerase-1 inhibitor (PJ34)+VILI group
trd-60-451-g002
Figure 3
Acute lung injury score (A) and wet-to-dry weight ratio (B) were significantly different among the groups (p=0.000 and p=0.001 by Kruskal-Wallis test, respectively) and higher in the VILI group than the other groups (*p<0.05, compared with other groups).
Sham: sham group, LPV: lung protective ventilation group, VILI: ventilator-induced lung injury group, PJ34+VILI: poly(ADP-ribose) polymerase-1 inhibitor (PJ34)+VILI group
trd-60-451-g003
Figure 4
In immunohistochemical method utilizing biotinylated NAD, the cells with poly(ADP-ribose) polymerase-1 (PARP1) activity were stained as dark black color. In the VILI group, the number of cells with PARP1 activity enormously increased compared with the sham or LPV groups. After PARP1 inhibitor, PJ34, pretreatment, the PARP1 activity positive cells significantly decreased in the PJ34+VILI group.
Sham: sham group, LPV: lung protective ventilation group, VILI: ventilator-induced lung injury group, PJ34+VILI: poly(ADP-ribose) polymerase-1 inhibitor (PJ34)+VILI group
trd-60-451-g004
Figure 5
The number of cells with PARP1 activity in 5 high power fields (HPFs, ×400) (A) and myeloperoxidase (MPO) activity in bronchoalveolar lavage fluid (BALF) (B) were significantly different among the groups (p=0.002 and p=0.001 by Kruskal-Wallis test, respectively) and higher in the VILI group than the other groups (*p<0.05, compared with other groups). MPO activity of PJ34+VILI group was significantly higher than Sham and LPV group (†p<0.05)
Sham: sham group, LPV: lung protective ventilation group, VILI: ventilator-induced lung injury group, PJ34+VILI: poly(ADP-ribose) polymerase-1 inhibitor (PJ34)+VILI group
trd-60-451-g005
Figure 6
The concentration of tumor necrosis factor (TNF)-α (A), interleukin (IL)-1β (B), and IL-6 (C) in bronchoalveolar lavage fluid (BALF) were significantly higher in the VILI group than the other groups (*p<0.05, compared with other groups).
ELISA: enzyme-linked immuno-sorbent assay, ND: not detected, Sham: sham group, LPV: lung protective ventilation group, VILI: ventilator-induced lung injury group, PJ34+VILI: poly(ADP-ribose) polymerase-1 inhibitor (PJ34)+VILI group
trd-60-451-g006
Figure 7
Poly(ADP-ribose) polymerase-1 (PARP1) activity showed significant relationship with degree of acute lung injury (ALI) and inflammatory cytokines in bronchoalveolar lavage fluid (BALF) (r=Spearman's rho, *p<0.05 and **p<0.01).
HPF: high power field, TNF-α: tumor necrosis factor-α, IL-1β: interleukin-1β, IL-6: interleukin-6
trd-60-451-g007

References

1. International consensus conferences in intensive care medicine: ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societe de Reanimation de Langue Francaise, and was approved by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 1999. 160:2118–2124.
2. Slutsky AS, Tremblay LN. Multiple system organ failure: is mechanical ventilation a contributing factor? Am J Respir Crit Care Med. 1998. 157:1721–1725.
3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000. 342:1301–1308.
4. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998. 338:347–354.
5. Tremblay LN, Slutsky AS. Ventilator-induced injury: from barotrauma to biotrauma. Proc Assoc Am Physicians. 1998. 110:482–488.
6. Uhlig S, Uhlig U. Pharmacological interventions in ventilator-induced lung injury. Trends Pharmacol Sci. 2004. 25:592–600.
7. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004. 26:882–893.
8. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol. 2003. 31:446–454.
9. Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair. 2004. 3:1103–1108.
10. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Perez JM. Poly(ADP-ribose) polymerases: homology, structural domains and functions: novel therapeutical applications. Prog Biophys Mol Biol. 2005. 88:143–172.
11. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002. 54:375–429.
12. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999. 342:249–268.
13. Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001. 477:97–110.
14. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985. 101:4–15.
15. Berger NA, Berger SJ. Metabolic consequences of DNA damage: the role of poly (ADP-ribose) polymerase as mediator of the suicide response. Basic Life Sci. 1986. 38:357–363.
16. Berger NA, Whitacre CM, Hashimoto H, Berger SJ, Chatterjee S. NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Biochimie. 1995. 77:364–367.
17. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med. 1997. 3:1089–1095.
18. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A. 1999. 96:13978–13982.
19. Heller B, Wang ZQ, Wagner EF, Radons J, Burkle A, Fehsel K, et al. Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J Biol Chem. 1995. 270:11176–11180.
20. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A. 1996. 93:1753–1758.
21. Virag L, Salzman AL, Szabo C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol. 1998. 161:3753–3759.
22. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 1994. 263:687–689.
23. Zingarelli B, O'Connor M, Wong H, Salzman AL, Szabo C. Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol. 1996. 156:350–358.
24. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res. 1998. 83:85–94.
25. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med. 1998. 157:294–323.
26. Imanaka H, Shimaoka M, Matsuura N, Nishimura M, Ohta N, Kiyono H. Ventilator-induced lung injury is associated with neutrophil infiltration, macrophage activation, and TGF-beta 1 mRNA upregulation in rat lungs. Anesth Analg. 2001. 92:428–436.
27. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001. 7:108–113.
28. Zhang J. Use of biotinylated NAD to label and purify ADP-ribosylated proteins. Methods Enzymol. 1997. 280:255–265.
29. Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, et al. Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med. 2002. 165:372–377.
30. Hirano S. Migratory responses of PMN after intraperitoneal and intratracheal administration of lipopolysaccharide. Am J Physiol. 1996. 270:L836–L845.
31. Tsuno K, Miura K, Takeya M, Kolobow T, Morioka T. Histopathologic pulmonary changes from mechanical ventilation at high peak airway pressures. Am Rev Respir Dis. 1991. 143:1115–1120.
32. Woo SW, Hedley-Whyte J. Macrophage accumulation and pulmonary edema due to thoracotomy and lung over inflation. J Appl Physiol. 1972. 33:14–21.
33. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest. 1997. 99:944–952.
34. Matsuoka T, Kawano T, Miyasaka K. Role of high-frequency ventilation in surfactant-depleted lung injury as measured by granulocytes. J Appl Physiol. 1994. 76:539–544.
35. Sugiura M, McCulloch PR, Wren S, Dawson RH, Froese AB. Ventilator pattern influences neutrophil influx and activation in atelectasis-prone rabbit lung. J Appl Physiol. 1994. 77:1355–1365.
36. Takata M, Abe J, Tanaka H, Kitano Y, Doi S, Kohsaka T, et al. Intraalveolar expression of tumor necrosis factor-alpha gene during conventional and high-frequency ventilation. Am J Respir Crit Care Med. 1997. 156:272–279.
37. Okuyama K. Inflammatory chemical mediators during conventional ventilation and during high frequency oscillatory ventilation. Am J Respir Crit Care Med. 1994. 150:1550–1554.
38. Zhang H, Downey GP, Suter PM, Slutsky AS, Ranieri VM. Conventional mechanical ventilation is associated with bronchoalveolar lavage-induced activation of polymorphonuclear leukocytes: a possible mechanism to explain the systemic consequences of ventilator-induced lung injury in patients with ARDS. Anesthesiology. 2002. 97:1426–1433.
39. Jafari B, Ouyang B, Li LF, Hales CA, Quinn DA. Intracellular glutathione in stretch-induced cytokine release from alveolar type-2 like cells. Respirology. 2004. 9:43–53.
40. Li LF, Yu L, Quinn DA. Ventilation-induced neutrophil infiltration depends on c-Jun N-terminal kinase. Am J Respir Crit Care Med. 2004. 169:518–524.
41. Rimensberger PC, Fedorko L, Cutz E, Bohn DJ. Attenuation of ventilator-induced acute lung injury in an animal model by inhibition of neutrophil adhesion by leumedins (NPC 15669). Crit Care Med. 1998. 26:548–555.
42. Ohta N, Shimaoka M, Imanaka H, Nishimura M, Taenaka N, Kiyono H, et al. Glucocorticoid suppresses neutrophil activation in ventilator-induced lung injury. Crit Care Med. 2001. 29:1012–1016.
43. Chavolla-Calderon M, Bayer MK, Fontan JJ. Bone marrow transplantation reveals an essential synergy between neuronal and hemopoietic cell neurokinin production in pulmonary inflammation. J Clin Invest. 2003. 111:973–980.
44. Althaus FR, Kleczkowska HE, Malanga M, Muntener CR, Pleschke JM, Ebner M, et al. Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem. 1999. 193:5–11.
45. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999. 274:22932–22940.
46. Boulares AH, Zoltoski AJ, Yakovlev A, Xu M, Smulson ME. Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis. J Biol Chem. 2001. 276:38185–38192.
47. Ding R, Pommier Y, Kang VH, Smulson M. Depletion of poly(ADP-ribose) polymerase by antisense RNA expression results in a delay in DNA strand break rejoining. J Biol Chem. 1992. 267:12804–12812.
48. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005. 4:421–440.
49. Szabo C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med. 1997. 186:1041–1049.
50. Zingarelli B, Hake PW, O'Connor M, Denenberg A, Wong HR, Kong S, et al. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly (ADP-ribose) polymerase-1. Am J Physiol Heart Circ Physiol. 2004. 286:H1408–H1415.
51. Chapman KE, Sinclair SE, Zhuang D, Hassid A, Desai LP, Waters CM. Cyclic mechanical strain increases reactive oxygen species production in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005. 289:L834–L841.
52. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, Szabo C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001. 7:255–260.
TOOLS
Similar articles